CARDINAL HEALTH INC (CAH) Forecast, Price Target & Analyst Ratings
NYSE:CAH • US14149Y1082
217.76 USD
-4.52 (-2.03%)
Last: Mar 10, 2026, 03:29 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARDINAL HEALTH INC (CAH).
Forecast Snapshot
Consensus Price Target
$252.17
+ 15.80% Upside
Next Earnings Forecast
Release DateApr 29, 2026
PeriodQ3 / 2026
EPS Estimate$2.80
Revenue Estimate62.338B
ChartMill Buy Consensus
83.64%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$252.17
Upside
+ 15.80%
From current price of $217.76 to mean target of $252.17, Based on 22 analyst forecasts
Low
$171.03
Median
$260.10
High
$283.50
Price Target Revisions
1 Month
5.75%
3 Months
16.32%
Price Target Summary
22 Wall Street analysts provided a forecast for the next 12 months for CAH. The average price target is 252.17 USD. This implies a price increase of 15.8% is expected in the next year compared to the current price of 217.76.
The average price target has been revised upward by 16.32% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.64%
CAH was analyzed by 22 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CAH.
In the previous month the buy percentage consensus was at a similar level.
CAH was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-24 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-10 | JP Morgan | Maintains | Neutral -> Neutral |
| 2026-02-06 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-01-29 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-09 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-04 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-03 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-31 | UBS | Maintains | Buy -> Buy |
| 2025-10-31 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-31 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-08-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-08-12 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-07-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-13 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-13 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-06-12 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-06-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-03 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2025-05-05 | Morgan Stanley | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 29, 2026
PeriodQ3 / 2026
EPS Estimate$2.80
Revenue Estimate62.338B
Revenue Q2Q13.59%
EPS Q2Q19.18%
Number of Analysts17
Next Earnings Revisions
Revenue (1 Month)
-0.86%
Revenue (3 Months)
-0.41%
EPS (1 Month)
2.20%
EPS (3 Months)
2.50%
Next Earnings Summary
CAH is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 2.8 USD and the consensus revenue estimate is 62.34B USD.
The next earnings revenue estimate has been revised downward by 0.41% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 205.012B 13.04% | 226.827B 10.64% | 222.578B -1.87% | 261.251B 17.38% | 284.758B 9.00% | 306.956B 7.80% | 334.027B 8.82% | 360.085B 7.80% | |
| EBITDA YoY % growth | 2.466B 4.09% | 2.86B 15.98% | 3.273B 14.44% | 4.063B 24.14% | 4.461B 9.80% | 4.875B 9.28% | 5.918B 21.39% | N/A | |
| EBIT YoY % growth | 1.774B 5.78% | 2.15B 21.20% | 2.483B 15.49% | 3.501B 41.00% | 3.86B 10.25% | 4.214B 9.17% | 4.735B 12.36% | 5.209B 10.01% | |
| Operating Margin | 0.87% | 0.95% | 1.12% | 1.34% | 1.36% | 1.37% | 1.42% | 1.45% | |
| EPS YoY % growth | 5.81 14.82% | 7.47 28.57% | 8.24 10.31% | 10.41 26.31% | 11.69 12.35% | 13.08 11.89% | 14.92 14.04% | 16.79 12.51% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.80 19.18% | 2.36 13.48% | 2.70 5.88% | 2.66 1.06% | 3.05 8.85% | 2.59 9.62% | 2.91 7.92% | 2.83 6.40% | 3.21 5.19% | 2.86 10.67% |
| Revenue Q2Q % growth | 62.338B 13.59% | 66.931B 11.26% | 67.771B 5.88% | 69.594B 6.04% | 66.033B 5.93% | 71.865B 7.37% | 71.713B 5.82% | 73.875B 6.15% | 69.928B 5.90% | 76.427B 6.35% |
| EBITDA Q2Q % growth | 1.037B -20.96% | 919.19M -35.22% | 1.096B 9.16% | 1.058B -17.08% | 1.12B 8.00% | 1.033B 12.38% | 1.247B 13.78% | 1.178B 11.34% | 1.224B 9.29% | 1.153B 11.62% |
| EBIT Q2Q % growth | 947.75M 29.65% | 811.25M 28.97% | 926.84M 20.21% | 937.6M 15.90% | 1.026B 8.26% | 886.12M 9.23% | 985.15M 6.29% | 974.4M 3.92% | 1.093B 6.53% | 971.09M 9.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
16.66%
EPS Next 5 Year
15.29%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
10.82%
Revenue Next 5 Year
9.81%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
20.02%
EBIT Next 5 Year
20.36%
CARDINAL HEALTH INC / CAH Forecast FAQ
Can you provide the average price target for CARDINAL HEALTH INC stock?
22 analysts have analysed CAH and the average price target is 252.17 USD. This implies a price increase of 15.8% is expected in the next year compared to the current price of 217.76.
What is the next earnings date for CAH stock?
CARDINAL HEALTH INC (CAH) will report earnings on 2026-04-29, before the market open.
What are the consensus estimates for CARDINAL HEALTH INC (CAH) next earnings?
The consensus EPS estimate for the next earnings of CARDINAL HEALTH INC (CAH) is 2.8 USD and the consensus revenue estimate is 62.34B USD.
What is the consensus rating for CAH stock?
The consensus rating for CARDINAL HEALTH INC (CAH) is 83.6364 / 100 . This indicates that analysts generally have a positive outlook on the stock.